Unlock the Future of Cell Analysis with Celledonia™

10 June 2024: Meet Celledonia™, the new and revolutionary benchtop cell analyser that will inform and expedite your bioprocesses and turn your data into actionable insights.

TechBio company Cytomos (www.cytomos.com) today announces the launch of its much-anticipated flagship benchtop solution Celledonia™, which uses the company’s patented AuraCyt™ platform.

Celledonia™ – a benchtop cell analyser – provides rapid, unbiased and intuitive cell-specific insights. This has the potential to revolutionise biotech, from development to manufacturing. It will reduce development and technology transfer timelines, costs, labour and time-to-market for modalities including monoclonal antibodies (mAbs), T cell immunotherapies, and induced pluripotent stem cells (iPSCs). The new technology can help to:

• Predict cell health, type, and functions for T cell-based immunotherapy development;
• Provide near-real time information about the state and age of cell populations;
• Signal optimal time for harvesting;
• Select high-producing, stable clones for CHO CLD of mAbs;
• Inform pluripotent expansion and differentiation strategy for stem cells.

Insights such as these unlock exponential value for the bioprocess industry, enabling rapid decision making and live process control. Celledonia™ makes it possible to improve and streamline cell line development and bioproduction processes, while improving CGT process control should enable earlier prediction of product failure or success.

Celledonia™ leverages the power of Cytomos’ AuraCyt™ platform, which integrates a proprietary semiconductor chip with narrow-channel fluidics that focus cells (5-30 μm) close to the surface of the chip. As the cells pass through an electric field, the sensors provide a unique ‘fingerprint’ of the cell, analysing a range of cell features simultaneously. The resulting data represent intrinsic cellular properties in near-real-time, delivering label-free, consistent, accurate and reliable cell analytics.

Cytomos CEO David Rigterink commented, “Celledonia™ finally enables more timely, game-changing decisions via its patented real-time AuraCyt™ platform by agnostically translating complex cell data into actionable insights. That offers the potential to greatly accelerate and improve Cell Line Development, CAR-T manufacturing efficacy and iPSC productivity. By harnessing the power of dielectric spectroscopy and microelectronics, we can improve the pace and accuracy of single cell analysis. The technology fits into an evolving landscape of next-generation therapies that are driving the need for radical advances in cell analytics.”

Celledonia™ is designed for ease-of-use, to allow users across R&D laboratories and manufacturing sites to generate consistent, reliable and informative cell analytics in near real-time. It overcomes the limitations of many conventional cell analytic technologies by removing many of the obstacles that prevent quick and unbiased decision making, such as operator bias, the need for labels, or the generation of indigestible data.

Dr Fernanda Masri, the company’s Chief Commercial and Innovation Officer, and former Head of Innovation Manufacturing and Collaborations at CGT Catapult explains, “There is no need for markers or cell preparation, yet a multitude of single-cell attributes can be detected without operator bias. Simply load your cells directly from culture onto the Celledonia™ instrument and run your samples to generate data that the software turns into useful insights in mere minutes, rather than taking hours, or up to days to get results.”

Celledonia™ could provide the answers you are looking for, to achieve near real-time, reliable and consistent single-cell analytics. Get in touch with the Cytomos team at www.cytomos.com/contact-cytomos to find out how Celledonia™ can help you.